Founder and Chief Executive Officer-
Dr Andrew Kuper is an award-winning entrepreneur, investor and author. He founded LeapFrog Investments in 2007 and serves as CEO. Today, LeapFrog’s companies serve 111 million people across Africa, Asia and Latin America with financial tools and healthcare. Since investment, portfolio companies have grown on average 43.3% per year. They support over 114,626 jobs across 33 countries.
Many of the world’s leading financial institutions have committed over USD1 billion to LeapFrog to invest, including ten of the largest global pensions and insurance groups. At the same time, tens of millions of low-income people whom LeapFrog companies serve are accessing quality insurance, savings, pensions, credit, payments or healthcare for the first time.
In 2017, LeapFrog was named by Fortune as one of the top 5 Companies to Change the World, alongside Apple and Novartis. Dr Kuper was previously hailed by The Economist group for demonstrating how “to change the way we invest as individuals, institutions and societies”. President Clinton has recognised him for “opening up new frontiers for alternative investment”.
For his work as a pioneer of profit with purpose business, Dr Kuper won the Ernst & Young National Entrepreneur of the Year award. He also received the SEN Leadership Award from among the 25,000 chief executive members of YPO.
Dr Kuper is currently a Board member of GPCA and a member of the global AXA Stakeholder Panel. He is a founding member of the Advisory Boards of In-Films and Purpose.com, which both use social media and film to build social-purpose movements.
Born and raised in South Africa, Dr Kuper holds a PhD in Social and Political Sciences from Cambridge University, supervised by Nobel Laureate Amartya Sen and ethicist Baroness Onora O’Neill. He has been an academic or visiting scholar at Cambridge, Harvard and Columbia.
Dr Kuper is the author of two books and many articles on globalization and governance, and co-author of publications with diverse leaders and Nobel laureates.